Goodyear Tire & Rubber Co vs Oruka Therapeutics Inc. Common Stock — how do they compare? Goodyear Tire & Rubber Co trades at $4.41 (market cap $1.26B), while Oruka Therapeutics Inc. Common Stock trades at $76.8 (market cap $5.08B). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 4× Goodyear Tire & Rubber Co's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Goodyear Tire & Rubber Co for 58 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| GT | ORKA | |
|---|---|---|
Market Cap | $1.26B | $5.08B |
Volume | 7,768,478 | 685,276 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $113.08 |
52-Week Low | $4.38 | $26.19 |
Typical Hold Time | 58 Days | 0 Days |
Enterprise Value | $8.61B | $4.21B |
Signals from Pluang's Aura AI — not financial advice
GT trades at $4.56, up 1.56% on the day, but remains in a bearish technical trend with the stock near its 52-week low. The company reported a net loss of $1.72 billion in 2025, with negative profit margins and ROE, though it beat Q1 and Q2 2026 EPS estimates. Cash flow from operations improved to $796 million in 2025, but high debt levels and restructuring efforts under a new strategy are key focal points.
The outlook is challenged by persistent losses and volume pressure, but analyst consensus suggests upside with a $8.00 price target. Investment opportunity hinges on successful execution of the margin-focused turnaround; key risks include execution missteps, competitive pressures, and macroeconomic headwinds affecting tire demand.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →